Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is
often associated with an aggressive phenotype and a poor prognosis. Cytotoxic …

BACKGROUND: Triple-negative breast cancer (TNBC) is a biologically heterogeneous
disease that is often associated with worse outcomes compared with other subtypes such as …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Background One of the front treatment regimens used for metastatic triple-negative breast
cancer (mTNBC) is treatment with programmed death-1 (PD-1) or programmed death ligand …

Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …

Triple-negative breast cancer (TNBC), as defined by the absence of estrogen receptor,
progesterone receptor and human epidermal growth factor receptor 2 expression, is a …

Triple-negative breast carcinoma (TNBC) remains a formidable clinical hurdle owing to its
high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of …

Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor,
human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is …

Patients with breast tumors that do not express the estrogen receptor, the progesterone
receptor, nor Her-2/neu are hence termed “triple negatives”, and generally have a poor …

Triple-negative breast cancer (TNBC) is a heterogeneous disease with a complex biology
and high metastatic potential, defined by negative immunohistochemistry (IHC) for hormonal …